Brought to you by 
Aldea Pharmaceuticals closes $24mm Series B round
15 Dec 2015
Executive Summary
Aldea Pharmaceuticals (aldehyde metabolism disorders) closed a $24mm Series B round through new investors Russian biotechnology incubator RusnanoMedInvest and Chinese CRO WuXi PharmaTech’s venture arm WuXi PharmaTech Corporate Ventures, as well as returning backers that included Canaan Partners and Correlation Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aldea Pharmaceuticals closes $24mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice